Photo illustration by Slate. Photo by Marc Bruxelle/iStock/Getty Images Plus.
This post is part of Outward, Slate’s home for coverage of LGBTQ life, thought, and culture. Read more here.
An Australian man recently made headlines as the seventh reported case, worldwide, of a failure of PrEP (Pre-Exposure Prophylaxis), the groundbreaking drug regimen shown to be 99 percent effective at preventing HIV infection with daily adherence. While understandably disconcerting for users, PrEP failures are major news because they are so rare—and Truvada (tenofovir disoproxil fumarate/emtricitabine), the drug used for PrEP, is unquestionably one of the best tools we have for stopping the spread of HIV. Read More
